This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Evolent Health (EVH) Isn't Done Growing Earnings Yet
by Zacks Equity Research
Evolent Health (EVH) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Evolent Health (EVH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 20.00% and 5.10%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Evolent Health (EVH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Evolent Health (EVH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolent Health (EVH) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
Evolent Health (EVH) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Evolent Health (EVH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 25.00% and 1.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Has Evolent Health (EVH) Outpaced Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (EVH) Outperforming Other Computer and Technology Stocks This Year?
Evolent Health (EVH) Posts Q2 Loss as Expected, Revenues Top
by Zacks Equity Research
Evolent Health's (EVH) strong rise in the number of members on its platform was the key highlight of the second quarter.
Evolent Health (EVH) Prices 4.5M Follow-On Share Offering
by Zacks Equity Research
Evolent Health, Inc. (EVH) recently announced the pricing of its follow-on public offering of 4.5 million shares of Class A common stock at $25.90 per share.
Evolent Health (EVH) Prices 7M Follow-On Share Offering
by Zacks Equity Research
Evolent Health, Inc. (EVH) recently announced the pricing of its follow-on public offering of 7.5 million shares of Class A common stock at $24.65 per share.
Evolent Health (EVH) Prices 7.5M Follow-On Share Offering
by Zacks Equity Research
Evolent Health, Inc. (EVH) announced the pricing of its follow-on public offering of 7.5 million shares of Class A common stock at $21.25 per share.